ABL Diagnostics obtained CE-IVD registration for a set of molecular tests spanning HIV-1 genotyping, respiratory pathogens, and viral meningitis. The PCR-based DeepChek Whole Genome HIV-1 Genotyping assay targets antiviral resistance-relevant mutations via viral genome amplification from blood samples. Its portfolio also includes UltraGene multiplex respiratory testing and multiplex viral meningitis pathogen detection from cerebrospinal fluid, while the company separately amended financing terms to adjust operating conditions and tighten resales constraints around its equity line.